Mobile website
Archive > Volume 26 Issue 2 > 2019,26(2):137-145. DOI:10.3872/j.issn.1007-385X.2019.02.001 Prev Next
Expert Forum
Immunotherapy for lung cancer: new era, new thinking
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] In recent years, immune checkpoint inhibitors have been continuously researched and developed, and gradually expanded in clinical practice, rapidly changing the treatment mode of lung cancer. At present, a number of immunotherapeutic drugs are also actively developed in China and gradually applied to clinical research, indicating that China has entered a new era of immunotherapy.However, with the continuous expansion of clinical research and the continuous accumulation of experimental data, it also brings us many new challenges and new thinking. This article mainly analyzes the development status and challenges of immunotherapy for lung cancer in the aspects of breakthroughs in treatment modes, special populations excluded from clinical immunotherapy trials, response evaluation, treatment-related adverse events and predictive biomarkers.
Keywords:
Project Supported:
Project supported by the National Key Research and Development Program of China (No.2016YFC1303800), the National Natural Science Foundation of China (No.81672275), the Key Laboratory Construction Project of Department of Science and Technology of Jilin Province (No. 20170622011JC), the Special Project of Development and Reform Commission in Jilin Province (No. 2017C022), and the Special Project of the National Health and Family Planning Commission of China (No. ZX-07-C2016004)
Clc Number:
